Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels

被引:16
|
作者
Lee, Chan Joo [1 ,2 ]
Lee, Yunbeom [3 ]
Park, Sungha [1 ,2 ]
Kang, Seok-Min [1 ,2 ]
Jang, Yangsoo [1 ,2 ]
Lee, Ji Hyun [4 ]
Lee, Sang-Hak [1 ,2 ]
机构
[1] Yonsei Univ, Coll Med, Severance Hosp, Div Cardiol,Dept Internal Med, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Cardiovasc Res Inst, Seoul, South Korea
[3] Kyung Hee Univ, Grad Sch, Dept Med, Seoul, South Korea
[4] Kyung Hee Univ, Coll Med, Dept Clin Pharmacol & Therapeut, Seoul, South Korea
来源
PLOS ONE | 2017年 / 12卷 / 10期
基金
新加坡国家研究基金会;
关键词
APOLIPOPROTEIN-B; GENETIC-VARIANTS; FAMILIAL HYPOBETALIPOPROTEINEMIA; MOLECULAR DIAGNOSIS; HEART-DISEASE; FATTY LIVER; LOW LDL; MUTATIONS; JAPANESE; DYSLIPIDEMIAS;
D O I
10.1371/journal.pone.0186446
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Screening of variants, related to lipid metabolism in patients with extreme cholesterol levels, is a tool used to identify targets affecting cardiovascular outcomes. The aim of this study was to examine the prevalence and characteristics of rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol (LDLC) levels. Methods Among 13,545 participants enrolled in a cardiovascular genome cohort, 22 subjects, whose LDL-C levels without lipid-lowering agents were <= 1 percentile (48 mg/dL) of Korean population, were analyzed. Two target genes, APOB and PCSK9, were sequenced by targeted next-generation sequencing. Prediction of functional effects was conducted using SIFT, PolyPhen-2, and Mutation Taster, and matched against a public database of variants. Results Eight rare variants of the two candidate genes (five in APOB and three in PCSK9) were found in nine subjects. Two subjects had more than two different rare variants of either gene (one subject in APOB and another subject in APOB/PCSK9). Conversely, 12 common variants (nine in APOB and three in PCSK9) were discovered in 21 subjects. Among all variants, six in APOB and three in PCSK9 were novel. Several variants previously reported functional, including c. C277T (p. R93C) and c. G2009A (p. G670E) of PCSK9, were found in our population. Conclusions Rare variants of APOB or PCSK9 were identified in nine of the 22 study patients with extremely low LDL-C levels, whereas most of them had common variants of the two genes.The common novelty of variants suggested polymorphism of the two genes among them. Our results provide rare genetic information associated with this lipid phenotype in East Asian people.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Gender differences low-density lipoprotein cholesterol reduction with PCSK9 inhibitors in real world patients
    Cordero, A.
    Fernandez Del Olmo, M. R.
    Cortez Quiroga, G. A.
    Romero, C.
    Facila, L.
    Fornovi, A.
    Rondan, J.
    Bello Mora, M. C.
    Valle, A.
    Sandin, A. L. B. E. R. T.
    Freixa, R.
    Sanchez-Alvare, S.
    Blanch, P.
    Clemente Lorente, M.
    Gonzalez-Juanatey, J. R.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2589 - 2589
  • [22] Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
    Shapiro, Michael D.
    Minnier, Jessica
    Tavori, Hagai
    Kassahun, Helina
    Flower, Andrea
    Somaratne, Ransi
    Fazio, Sergio
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (04):
  • [23] A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels
    Tremblay, Frederic
    Xiong, Qiang
    Shah, Shrijal S.
    Ko, Chih-Wei
    Kelly, Kenneth
    Morrison, Mary S.
    Giancarlo, Cristiana
    Ramirez, Ricardo N.
    Hildebrand, Erica M.
    Voytek, Sarah B.
    El Sebae, Gabriel K.
    Wright, Shane H.
    Lofgren, Liam
    Clarkson, Scott
    Waters, Christine
    Linder, Samantha J.
    Liu, Songlei
    Eom, Taesun
    Parikh, Shefal
    Weber, Yuki
    Martinez, Salette
    Malyala, Padma
    Abubucker, Sahar
    Friedland, Ari E.
    Maeder, Morgan L.
    Lombardo, Angelo
    Myer, Vic E.
    Jaffe, Aron B.
    NATURE MEDICINE, 2025, : 1329 - 1338
  • [24] Multiple rare and common variants in APOB gene locus associated with oxidatively modified low-density lipoprotein levels
    Khlebus, Eleonora
    Kutsenko, Vladimir
    Meshkov, Alexey
    Ershova, Alexandra
    Kiseleva, Anna
    Shevtsov, Anton
    Shcherbakova, Natalia
    Zharikova, Anastasiia
    Lankin, Vadim
    Tikhaze, Alla
    Chazova, Irina
    Yarovaya, Elena
    Drapkina, Oksana
    Boytsov, Sergey
    PLOS ONE, 2019, 14 (05):
  • [25] Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables
    Filippatos, Theodosios D.
    Kei, Anastazia
    Rizos, Christos V.
    Elisaf, Moses S.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 23 (01) : 3 - 12
  • [26] PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity Reply
    Koren, Michael J.
    Sabatine, Marc S.
    JAMA CARDIOLOGY, 2017, 2 (10) : 1169 - 1169
  • [27] Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?
    Farnier, Michel
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
  • [28] Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
    Sinning, David
    Landmesser, Ulf
    CURRENT CARDIOLOGY REPORTS, 2020, 22 (12)
  • [29] Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
    David Sinning
    Ulf Landmesser
    Current Cardiology Reports, 2020, 22
  • [30] PCSK9 Inhibitors: The Next Frontier in Low-Density Lipoprotein Lowering
    Jialal, Ishwarlal
    Patel, Shailendra B.
    METABOLIC SYNDROME AND RELATED DISORDERS, 2015, 13 (03) : 99 - 101